Lentiviral-Based Anti-HIV Therapeutic Vaccine: Design, Preclinical Studies and PhaseI/II Clinical Trial Preliminary Results

Background: Theravectys, a spin-off the Pasteur Institute, develops a new generation of prophylactic and therapeutic vaccines using optimized lentiviral vectors. It's most advanced product, a therapeutic anti-HIV vaccine treatment, has entered clinical Phase I/II end of 2012. This vaccination should allow seropositive patients to gain an immunological status identical to the so-called "Functional Cured" patients who develop an efficient immunological response capable of controlling the infection without therapy.